Evident Vascular is a San Jose–based medical technology company developing a next-generation intravascular ultrasound (IVUS) platform powered by artificial intelligence. Its core product integrates AI to enhance vascular image interpretation, streamline clinical workflows, and support peripheral and complex coronary interventions. The company plans to use Series B proceeds to accelerate platform development and pursue 510(k) FDA clearance ahead of a U.S. market launch. It recently closed a Series B financing with new investor Shangbay Capital and two undisclosed multinational strategic investors joining founding investor Vensana Capital. Leadership, including CEO and co-founder Howard Rosen, emphasize expanding IVUS adoption by increasing its utility and accessibility in clinical practice. Evident positions its solution to improve diagnostic guidance and procedural success consistent with clinical evidence and contemporary guidelines. Evident Vascular is developing an advanced intravascular ultrasound (IVUS) platform designed initially for peripheral vascular interventions with future capability for coronary procedures. The platform leverages artificial intelligence to enable superior image interpretation and streamlined clinical workflows. The company positions its technology to address shortcomings in legacy IVUS systems, including image quality, interpretation, and workflow limitations. Evident says the platform is designed to expand IVUS adoption, drive increased market penetration, and enable faster, more accurate diagnosis and treatment decisions. The company launched from stealth with a $35 million Series A financing provided by Vensana Capital to support development. Evident is led by CEO and co‑founder Howard Rosen, with Patrick Phillips, Ph.D., as CTO and Danielo Piazza as Chief Product Officer, and is based in San Jose, California.

Total raised

$35M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2023